(Q39586890)

13 September 2017

title

Antimicrobial susceptibility and synergy studies of cystic fibrosis sputum by direct sputum sensitivity testing (English)

1 reference

13 September 2017

0 references

0 references

D J Serisier

1

1 reference

13 September 2017

A Tuck

2

1 reference

13 September 2017

D Matley

3

1 reference

13 September 2017

M P Carroll

4

1 reference

13 September 2017

G Jones

5

1 reference

13 September 2017

publication date

12 July 2012

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

13 September 2017

published in

1 reference

13 September 2017

volume

31

1 reference

13 September 2017

issue

11

1 reference

13 September 2017

page(s)

3211-3216

1 reference

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Clinical application of direct sputum sensitivity testing in a severe infective exacerbation of cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Editorial overview: clinical utility of synergy testing for multidrug resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22790537

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22790537

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22790537

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10096-012-1687-6

1 reference

13 September 2017

1 reference